Cochrane · systematic review · CD006784
Antibiotic therapy for Shigella dysentery
Christopher, PRH, David, KV, John, SM, et al. · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
34
current version
GRADE rated
16
No studies
17
Included studies
NR
No studies 17 · 50%Ungraded 1 · 2.9%Very low 16 · 47.1%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsAntibiotic versus no drug or placebo for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea on Antibiotic vs no drug or placebo | RR 0.21 [0.09, 0.48] | 1 study · 73 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Diarrhoea on Antibiotic vs no drug or placebo | RR 0.3 [0.15, 0.59] | 1 study · 76 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse ‐ not reported Antibiotic vs no drug or placebo | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Antibiotic vs no drug or placebo | no estimate extracted | NR | No studies |
Other adverse events clinical criteria Antibiotic vs no drug or placebo | RR 1.43 [0.06, 34.13] | 1 study · 94 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Fluoroquinolones versus beta‐lactams for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea on Fluoroquinolones vs beta‐lactams | RR 1.03 [0.45, 2.37] | 6 studies · 686 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Relapse ‐ All trials clinical criteria Fluoroquinolones vs beta‐lactams | RR 0.91 [0.11, 7.55] | 3 studies · 357 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Serious adverse events clinical criteria Fluoroquinolones vs beta‐lactams | RR 10.9 [0.61, 194.82] | 1 study · 221 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adverse events leading to discontinuation of treatment Fluoroquinolones vs beta‐lactams | RR 1.02 [0.27, 3.89] | 1 study · 127 participants | Very low Downgraded: imprecision, indirectness |
Other adverse events clinical criteria Fluoroquinolones vs beta‐lactams | RR 1.03 [0.77, 1.39] | 4 studies · 570 participants | Very low Downgraded: imprecision, inconsistency, indirectness |
Fluoroquinolones versus macrolides for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea on Fluoroquinolones vs macrolides | RR 0.6 [0.24, 1.49] | 2 studies · 189 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Relapse ‐ not reported Fluoroquinolones vs macrolides | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Fluoroquinolones vs macrolides | no estimate extracted | NR | No studies |
Other adverse events clinical criteria Fluoroquinolones vs macrolides | RR 1.33 [0.32, 5.56] | 1 study · 76 participants | Very low Downgraded: imprecision, indirectness |
Cotrimoxazole versus beta‐lactams for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea on Cotrimoxazole vs beta‐lactams | RR 0.59 [0.23, 1.49] | 2 studies · 89 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Relapse ‐ not reported Cotrimoxazole vs beta‐lactams | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Cotrimoxazole vs beta‐lactams | no estimate extracted | NR | No studies |
Other adverse events clinical criteria Cotrimoxazole vs beta‐lactams | RR 0.81 [0.27, 2.45] | 2 studies · 89 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Cotrimoxazole versus fluoroquinolones (norfloxacin) for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea on Cotrimoxazole vs fluoroquinolones (norfloxacin) | no estimate extracted | NR | No studies |
Relapse ‐ not reported Cotrimoxazole vs fluoroquinolones (norfloxacin) | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Cotrimoxazole vs fluoroquinolones (norfloxacin) | no estimate extracted | NR | No studies |
Other adverse events clinical criteria Cotrimoxazole vs fluoroquinolones (norfloxacin) | RR 2.82 [0.12, 66.62] | 1 study · 62 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Cotrimoxazole versus furazolidone for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea on Cotrimoxazole vs furazolidone | RR 0.71 [0.27, 1.84] | 1 study · 101 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse ‐ not reported Cotrimoxazole vs furazolidone | no estimate extracted | NR | No studies |
Serious adverse events Cotrimoxazole vs furazolidone | RR 0 [0, 0] | 0 studies · 0 participants | Ungraded |
Other adverse events ‐ not reported Cotrimoxazole vs furazolidone | no estimate extracted | NR | No studies |
Oral gentamicin versus nalidixic acid for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea at Oral gentamicin vs nalidixic acid | RR 1.71 [0.98, 2.97] | 1 study · 79 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse ‐ not reported Oral gentamicin vs nalidixic acid | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Oral gentamicin vs nalidixic acid | no estimate extracted | NR | No studies |
Other adverse events ‐ not reported Oral gentamicin vs nalidixic acid | no estimate extracted | NR | No studies |
Sulphonamides versus tetracycline for Shigella dysentery
Population: patients with Shigella dysentery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Diarrhoea at Sulphonamides vs tetracycline | RR 7.68 [0.46, 128.12] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse ‐ not reported Sulphonamides vs tetracycline | no estimate extracted | NR | No studies |
Serious adverse events ‐ not reported Sulphonamides vs tetracycline | no estimate extracted | NR | No studies |
Other adverse events ‐ not reported Sulphonamides vs tetracycline | no estimate extracted | NR | No studies |